Journal Scan / Research · July 08, 2019
The authors concluded that enzalutamide in combination with androgen-deprivation therapy (ADT) is superior to ADT plus standard antiandrogen therapy and leads to an improvement in overall survival. Docetaxel-pretreated patients have a higher incidence of adverse events. Further data will need to clarify the optimal sequence and utility of chemotherapy and ADT.
-Gautam Jayram,
This treatment for mHSPCa has been reported on by different contributors. To me this begs the question is this more effective than abiraterone (Zytiga) together with standard ADT (Lupron)? I gather the answer is we don’t know.
Advanced Metastatic Prostate Cancer
Progressing metastatic prostate cancer
Both apalutamide and enzalutamide succeed for metastatic hormone-sensitive prostate cancer (mHSPC) - enzalutamide not for high volume mets
Update On My Metastatic Prostate Cancer 
Cardiotoxicity of Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
